Gonorrhea
Sexually Transmitted Disease Surveillance 2008
Division of STD Prevention
Gonorrhea — Rates: United States, 1941–2008
0
100
200
300
400
500
1941 46 51 56 61 66 71 76 81 86 91 96 2001 06
Rate (per 100,000 population)
Gonorrhea — Rates: Total and by sex: United States, 1989–2008
0
80
160
240
320
400
1989 91 93 95 97 99 2001 03 05 07
Rate (per 100,000 population)
MenWomenTotal
Gonorrhea — Rates by region: United States, 1999–2008
0
60
120
180
240
300
1999 2000 01 02 03 04 05 06 07 08
Rate (per 100,000 population)
WestMidwestNortheastSouth
Gonorrhea — Rates by state: United States and outlying areas, 2008
Note: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 110.3 per 100,000 population.
Rate per 100,000population
Guam 62.8
Puerto Rico 6.9
Virgin Is. 109.3
<=19.0
19.1-100.0
>100
(n= 7)
(n= 24)
(n= 23)
VT 6.0NH 7.6MA 33.0RI 29.0CT 80.0NJ 61.0DE 120.8MD 118.6DC 451.5
210.5
84.6
54.4 159.2
70.5 77.3
127.8
170.5
47.5
12.5
160.9 138.2
56.9
81.9107.2
220.2
7.3
169.4
58.4
256.8
136.3
12.7
82.384.7
71.2
88.7
176.3
22.4
146.5
143.3
32.7
89.0
214.2
47.1
142.6
134.7
18.0134.0
48.3
41.2
108.7
23.7
Gonorrhea — Rates by county: United States, 2008
Rate per 100,000population
<=19.0 (n= 1,305)
19.1-100.0 (n= 1,136)
>100.0 (n= 700)
Gonorrhea — Age- and sex-specific rates: United States, 2008
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
5.8 31.010-14278.3 636.815-19
433.6 608.620-24269.9 269.425-29
163.3 119.030-3499.6 55.235-39
71.7 28.940-4440.1 11.245-54
14.0 2.555-643.5 0.565+
103.3 119.7Total
Gonorrhea — Age-specific rates among women 15 to 44 years of age:United States, 1999–2008
0
200
400
600
800
1,000
1999 2000 01 02 03 04 05 06 07 08
Rate (per 100,000 population)
15-19 20-2425-29 30-3435-39 40-44
Gonorrhea — Age-specific rates among men 15 to 44 years of age:United States, 1999–2008
0
150
300
450
600
750
1999 2000 01 02 03 04 05 06 07 08
Rate (per 100,000 population)
15-19 20-2425-29 30-3435-39 40-44
Gonorrhea — Rates by race/ethnicity: United States, 1999–2008
0
180
360
540
720
900
1999 2000 01 02 03 04 05 06 07 08
Rate (per 100,000 population)
American Indian/AK NativeAsian/Pacific IslanderBlackHispanicWhite
Gonorrhea — Cases by reporting source and sex: United States, 1999–2008
0
40
80
120
160
200
1999 2000 01 02 03 04 05 06 07 08
Cases (in thousands)
non-STD Clinic Malenon-STD Clinic FemaleSTD Clinic MaleSTD Clinic Female
Gonorrhea — Positivity among 15- to 24-year-old women tested in family planning
clinics by state: United States and outlying areas, 2008
*States/areas not meeting minimum inclusion criteria.Note: Includes states and outlying areas that reported positivity data on at least 500 women aged 15-24 years screened during 2008.
DATA SOURCE: Prevalence Monitoring Project (Regional Infertility Prevention Projects), Office of Population Affairs, Local and State STD Control Programs, Centers for Disease Control and Prevention.
Positivity (%)
Puerto Rico 0.2
Virgin Is. 3.0
See*
<1.0
1.0-1.9
>=2.0
(n= 7)
(n= 23)
(n= 14)
(n= 9)
VT 0.0NHMARI 0.3CT 0.7NJ 1.3DE 1.4MDDC 2.0
2.7
0.2
0.6 1.9
0.8 0.4
1.7
2.2
0.8
0.1
1.4 1.4
0.5
1.00.6
2.4
0.0
1.4
0.5
2.9
1.0
1.0
0.91.8
0.6
0.5
1.4
1.6
0.8
0.9
2.50.8
2.1
0.31.20.4
3.8
0.4
Gonococcal Isolate Surveillance Project (GISP) — Location of participating sentinel sites and regional laboratories in the United States, 2008
Sentinel SitesSites and Regional Labs
Birmingham Phoenix
Los Angeles
Orange Co. San Diego
San Francisco Denver
Miami
Atlanta
Honolulu Tripler AMC
Chicago
New Orleans
Baltimore
Detroit Minneapolis
Kansas City
Las Vegas
Albuquerque
New York City
Greensboro
Cincinnati Cleveland
Oklahoma City
Portland
Philadelphia
Dallas
Richmond
Seattle
Gonococcal Isolate Surveillance Project (GISP) — Distribution of MICs to ceftriaxzone among GISP isolates, 2004–2008
Percent
MIC (µg/ml)
2004
2005
2006
2007
2008
0
20
40
60
80
100
<=0.008 0.015 0.03 0.06 0.125 0.25
Gonococcal Isolate Surveillance Project (GISP) — Distribution of MICs to azithromycin among GISP isolates, 2004–2008
Percent
MIC (µg/ml)
2004
2005
2006
2007
2008
0
12
24
36
48
60
<=0.03 0.06 0.125 0.25 0.5 1 2 4 8 16
Gonococcal Isolate Surveillance Project (GISP) — Percent of Neisseria gonorrhoeae isolates with resistance or intermediate resistance to ciprofloxacin,
1990–2008
Note: Resistant isolates have ciprofloxacin MICs ≥1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125 - 0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990.
Percent
ResistanceIntermediate resistance
0
4
8
12
16
1990 91 92 93 94 95 96 97 98 99 2000 01 02 03 04 05 06 07 08
Gonococcal Isolate Surveillance Project (GISP) — Penicillin, tetracycline, and ciprofloxacin resistance among GISP isolates, 2008
Note: PenR=penicillinase producing N. gonorrhoeae and chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR=chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; QRNG=ciprofloxacin resistant N. gonorrhoeae.
Gonococcal Isolate Surveillance Project (GISP) — Drugs used to treat gonorrhea in GISP patients, 1988–2008
0
20
40
60
80
100
1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
Other Cephalosporins
Ceftriaxone 125 mgSpectinomycin
Ceftriaxone 250 mg
Cefixime
Penicillins
Ciprofloxacin
Tetracyclines
Ofloxacin
Other
Note: For 2008, “Other” includes no therapy (1.3%), azithromycin 2 g (1.2%), levofloxacin (0.02%), and other less frequently used drugs.